A Study of RVT-1401 in Myasthenia Gravis (MG) Patients
Public ClinicalTrials.gov record NCT03863080. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension of RVT-1401 in Myasthenia Gravis Patients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the current study is to assess safety/tolerability and key pharmacodynamic (PD) effects that are considered to be associated with clinical benefit (reduction of total IgG and anti-AChR-IgG) in Myasthenia Gravis patients following treatment with RVT-1401 (also known as IMVT-1401) compared to placebo.
Study identification
- NCT ID
- NCT03863080
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 17 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 20, 2019
- Primary completion
- Oct 6, 2020
- Completion
- Dec 20, 2020
- Last update posted
- Dec 19, 2023
2019 – 2020
United States locations
- U.S. sites
- 15
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| IMC/Diagnostic and Medical Clinic | Mobile | Alabama | 36604 | — |
| Phoenix Neurological Associates | Phoenix | Arizona | 85018 | — |
| The Neurology Center of Southern California | Carlsbad | California | 92011 | — |
| UC Irvine - MDA ALS and Neuromuscular Center | Orange | California | 92868 | — |
| Care Access Research | Pasadena | California | 91101 | — |
| CSNA | Colorado Springs | Colorado | 80907 | — |
| Yale School of Medicine Department of Neurology | New Haven | Connecticut | 06510 | — |
| Neurological Services of Orlando | Orlando | Florida | 32806 | — |
| Rare Disease Research | Atlanta | Georgia | 30318 | — |
| University of Minnesota - Department of Neurology | Minneapolis | Minnesota | 55455 | — |
| Dent Institute | Amherst | New York | 14221 | — |
| University of Buffalo | Buffalo | New York | 14260-1660 | — |
| Hospital for Special Surgery | New York | New York | 10021 | — |
| Allegheny Neurological Associates | Pittsburgh | Pennsylvania | 15212 | — |
| UTSW James W. Aston Ambulatory Care Center - Neurology Clinic | Dallas | Texas | 75390 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03863080, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 19, 2023 · Synced Sep 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03863080 live on ClinicalTrials.gov.